Retinopathy Of Prematurity Market Size, Trends & Forecast Analysis

Retinopathy Of Prematurity Market Synopsis:

Retinopathy Of Prematurity Market Size Was Valued at USD 2.0 Billion in 2024, and is Projected to Reach USD 4.0 Billion by 2035, Growing at a CAGR of 6.0% From 2024-2035.

The Retinopathy of Prematurity (ROP) market, valued at $2.0 billion in 2024, is projected to reach $4.0 billion by 2035, growing at a compound annual growth rate (CAGR) of 6.0%. This expansion reflects the increasing prevalence of preterm births globally, with approximately 15 million premature infants born annually, heightening the demand for ROP screening, diagnosis, and treatment.

ROP, a leading cause of childhood blindness affecting 6-18% of cases in developed nations, arises from incomplete retinal vascular development in preterm infants exposed to supplemental oxygen. Advances in neonatal care have boosted survival rates of these infants, yet they remain vulnerable to severe ROP, necessitating early intervention through imaging, laser therapy, and anti-VEGF treatments.

Regionally, North America holds a dominant share due to advanced diagnostics, AI-enabled tools, and high ROP incidence among preterm births, while Asia Pacific emerges as the fastest-growing market with over 6.5% CAGR, driven by high preterm delivery rates in India and China.

Retinopathy Of Prematurity Market Trend Analysis:

Transition to Anti-VEGF Injections from Laser Therapy

• Healthcare providers are rapidly shifting from traditional laser photocoagulation to anti-VEGF injections like EYLEA (aflibercept), LUCENTIS (ranibizumab), and off-label bevacizumab for treating severe treatment-requiring ROP (TR-ROP). This transition is driven by anti-VEGF therapies' faster action, which blocks abnormal blood vessel growth in the retina more effectively than laser's destructive approach. In the 7 major markets (7MM), laser therapy still leads in revenue, but anti-VEGF agents are gaining as first-line options due to reduced treatment burden.
• EYLEA enables bedside administration in neonatal intensive care units (NICUs) without general anesthesia, unlike laser procedures that require specialized setups and longer recovery. This improves clinical workflows, especially for extremely premature infants with very low birth weight (VLBW). Studies show Japan has higher adoption rates of anti-VEGF therapies with earlier interventions compared to Western countries.
• Biosimilars like AVT06 to EYLEA are entering the market, enhancing affordability and access, particularly in emerging regions. This expansion is projected to revolutionize ROP dynamics as regulatory approvals accelerate time-to-market for these injectable options.

Adoption of AI-Powered Telemedicine Screening

• Improved retinal imaging and AI algorithms are transforming ROP screening by enabling remote diagnosis through telemedicine programs worldwide. Non-physician personnel capture digital images in NICUs, which AI analyzes for early detection of at-risk preterm infants, addressing the global shortage of skilled ophthalmologists. Baylor College of Medicine research highlights ROP's role in 6-18% of juvenile blindness in affluent nations, making scalable screening critical.
• Telemedicine initiatives collect vast datasets from sessions to train AI models, boosting diagnostic accuracy and supporting non-physician training programs. This has increased access in underserved areas, with North America leading due to advanced infrastructure while Asia-Pacific sees rapid growth from rising preterm births—over 15 million annually, led by India.
• Precision diagnostics like enhanced ophthalmoscopy combined with AI improve treatment planning, reducing irreversible vision loss that affects 32,300 newborns globally each year, including 20,000 cases of severe impairment or blindness.

Emergence of Prophylactic Preventive Therapies

• Novel preventive treatments targeting ROP pathophysiology, such as lipid peroxidation inhibitor FLQ-101 and probiotic IBP-1118, are entering clinical development to halt disease progression before severe stages. These therapies address the high burden in VLBW infants, complementing anti-VEGF and laser options by focusing on prevention amid rising preterm birth rates.
• With ROP causing legal blindness in 400-600 U.S. infants annually out of 14,000 preterm cases, and up to 10% requiring intervention, prophylactics promise to lower treatment needs. Fast Track designations are speeding approvals, expanding market dynamics beyond reactive therapeutics.
• Increasing neonatal care expenditures and standardized screening protocols are fueling investment in these emerging options, particularly in high-prevalence regions like Asia-Pacific where adolescent deliveries drive prematurity surges.

Retinopathy Of Prematurity Market Segment Analysis:

Retinopathy Of Prematurity Market is Segmented on the basis of By Treatment Type, By End User, By Disease Type

By Treatment Type, Laser Therapy segment is expected to dominate the market during the forecast period

• Laser therapy dominates due to its established efficacy in ablating avascular retina, reducing progression to retinal detachment in severe ROP cases.
• It remains the gold standard treatment recommended by international guidelines, with widespread availability in NICUs globally.

By End User, Hospitals segment is expected to dominate the market during the forecast period

• Hospitals lead as they house advanced NICUs equipped for ROP diagnosis and treatment by trained ophthalmologists and neonatologists.
• They provide comprehensive care including screening, monitoring, and intervention under one roof, driving higher procedure volumes.

By Disease Type, Partial Retinal Detachment segment is expected to dominate the market during the forecast period

• Partial retinal detachment segment dominates due to the urgent need for specialized surgical interventions like vitrectomy to prevent permanent vision loss.
• Advanced imaging and diagnostic tools are increasingly adopted for precise identification, boosting demand for related therapeutics and equipment.

By Region, North America segment is expected to dominate the market during the forecast period

• North America leads owing to advanced neonatal care infrastructure, high preterm survival rates, and widespread ROP screening programs in the US.
• Strong R&D investments and AI-enabled diagnostics further enhance early detection and treatment outcomes in the region.

Retinopathy Of Prematurity Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast Period

• North America dominates the Retinopathy of Prematurity market due to the high prevalence of the condition, particularly in the United States where around 14,000 preterm infants are born annually with ROP, and 10% (1,100 to 1,500) develop severe symptoms requiring intervention. In the U.S. and Canada, advanced neonatal care systems contribute to higher detection rates of ROP cases. This regional leadership is projected to continue, with North America expected to hold a 41% market share by 2035.
• The region benefits from a robust healthcare infrastructure, including state-of-the-art NICUs equipped with telemedicine and AI-driven screening tools for early ROP detection. Government-backed insurance policies for pediatric care in the U.S. and Canada enhance accessibility to treatments like laser therapy and anti-VEGF drugs. Continuous medical technology advancements and a focus on early intervention further solidify North America's market position.
• Key players are actively investing in R&D for ROP therapeutics, with recent developments in AI-enabled diagnostics and non-physician training programs improving care delivery. Major companies operate extensively in the U.S., driving innovations such as improved oxygen monitoring to prevent ROP progression. Collaborations between institutions like Baylor College of Medicine and industry leaders are accelerating treatment advancements in this region.

Active Key Players in the Retinopathy Of Prematurity Market:

• Novartis (Switzerland)
• Regeneron Pharmaceuticals (USA)
• Bayer (Germany)
• FeliQS Corporation (South Korea)
• Infant Bacterial Therapeutics (Sweden)
• Alvotech (Iceland)
• Visunex Medical Systems (USA)
• Merge Healthcare (USA)
• Natus Medical Incorporated (USA)
• Servicom Medical (USA)
• Advancing Eyecare (USA)
• Insmed Inc (USA)
• Alimera Sciences Inc. (USA)
• Biomar Microbial Technologies (Denmark)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Recordati S.p.A (Italy)
• SignaBlok Inc (USA)
• D. Western Therapeutics Institute Inc (Japan)
• Bausch Health Companies (Canada)
• Pfizer (USA)
• Other Active Players